Sign in Your account Book a briefing

About

Automation that increases control, not the opposite

Brain-Stem is an enterprise software delivery platform, built by people who have delivered enterprise software for decades.

Why we exist

Speed is the easy part. Keeping control is the hard part.

The problem we saw

Speed without control

AI changed what a small team can ship, and how quickly. But speed without control means the things serious organisations cannot lose, governance, traceability, a clear record of who decided what, quietly fall away. For a bank, a defence agency, or a government department, that trade is not acceptable.

What we built

Delivery that proves itself

Brain-Stem encodes your objectives, policies, and standards into how delivery actually runs. Every requirement, decision, and output is recorded and traceable, so delivery gets faster and cheaper and you can still prove exactly what was built and why. And it compounds: each engagement starts further ahead than the last.

What we stand for

Four principles we don't bend on

Control before autonomy

Autonomy only matters if you keep control. We never sell loss of control as a feature.

Evidence before claims

We earn trust by proving, not asserting. Every promise ties to a traceable record, a real number, or a concrete outcome.

An asset, not a tool

We build something that compounds with each engagement, not a product you rent and forget.

Human on purpose

In a cold, over-hyped industry, sounding and acting like people is a deliberate choice.

The team

The people behind it

We are a small, senior Australian team, with a board chair in Switzerland. The people who design, build, and sell the platform are the people you will work with.

Bruce Lock

Founder and CTO

Bruce Lock

More than 30 years building and shipping enterprise software. Bruce writes the platform day to day, on one idea: automation should increase control, not trade it away.

Myles Bertrand

CEO

Myles Bertrand

Around 25 years in payments, banking, and core-banking platforms, most recently as CEO of Tuum. Named one of the Top 50 fintech CEOs in 2024.

Michelle Lock

Chair of the board

Michelle Lock

A biopharma CEO and board leader with 24 years at Bristol-Myers Squibb. Her focus now is governance for AI companies in complex, regulated settings.

See it working on your delivery problem

Book a briefing to walk through your context, or take the assessment to see where you stand first.

Have a different question? Contact the team.